FAN1 modifies Huntington's disease progression by stabilising the expanded HTT CAG repeat by Goold, Robert et al.
†These authors should be regarded as joint first authors.
Received: September 12, 2018. Revised: October 15, 2018. Accepted: October 16, 2018
© The Author(s) 2018. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
650
Human Molecular Genetics, 2019, Vol. 28, No. 4 650–661
doi: 10.1093/hmg/ddy375
Advance Access Publication Date: 24 October 2018
General Article
G EN E RA L ART I C L E
FAN1 modifies Huntington’s disease progression by
stabilizing the expanded HTT CAG repeat
Robert Goold1,†, Michael Flower1,†, Davina Hensman Moss1, Chris Medway2,
Alison Wood-Kaczmar1, Ralph Andre1, Pamela Farshim1, Gill P. Bates1,3,
Peter Holmans2, Lesley Jones2 and Sarah J. Tabrizi1,3,*
1UCL Huntington’s Disease Centre,Department of Neurodegenerative Disease, Queen Square Institute of
Neurology, University College London,Queen Square, London WC1N 3BG, UK, 2Medical Research Council
Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, CF24 4HQ, UK and 3UK Dementia
Research Institute, University College London, WC1N 3BG, UK
*To whom correspondence should be addressed at: Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery,
University College London, Box 104, Queen Square, London WC1N 3BG, UK. Tel: +44 (0)2031087469; Fax: +44 02031087490; Email: s.tabrizi@ucl.ac.uk
Abstract
Huntington’s disease (HD) is an inherited neurodegenerative disease caused by an expanded CAG repeat in the huntingtin
(HTT) gene. CAG repeat length explains around half of the variation in age at onset (AAO) but genetic variation elsewhere in
the genome accounts for a significant proportion of the remainder. Genome-wide association studies have identified a
bidirectional signal on chromosome 15, likely underlain by FANCD2- and FANCI-associated nuclease 1 (FAN1), a nuclease
involved in DNA interstrand cross link repair. Here we show that increased FAN1 expression is significantly associated with
delayed AAO and slower progression of HD, suggesting FAN1 is protective in the context of an expanded HTT CAG repeat.
FAN1 overexpression in human cells reduces CAG repeat expansion in exogenously expressed mutant HTT exon 1, and in
patient-derived stem cells and differentiated medium spiny neurons, FAN1 knockdown increases CAG repeat expansion.
The stabilizing effects are FAN1 concentration and CAG repeat length-dependent. We show that FAN1 binds to the expanded
HTT CAG repeat DNA and its nuclease activity is not required for protection against CAG repeat expansion. These data shed
new mechanistic insights into how the genetic modifiers of HD act to alter disease progression and show that FAN1 affects
somatic expansion of the CAG repeat through a nuclease-independent mechanism. This provides new avenues for
therapeutic interventions in HD and potentially other triplet repeat disorders.
Introduction
Huntington’s disease (HD) is a dominantly inherited neurode-
generative condition caused by expansion of a CAG trinucleotide
repeat in the huntingtin (HTT) gene (1). TheCAG region translates
into an expanded polyglutamine stretch close to the N-terminus
of the HTT protein which confers a toxic gain of function. Longer
CAG repeats cause more severe disease, with earlier onset and
faster progression (2). CAG repeats are unstable and prone
to expansion during intergenerational germline transmission
(gametic instability) and in somatic tissues as they age [somatic
instability (SI)]. This is important because expansion is likely
to result in an HTT protein with a longer and more toxic
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Table 1. FAN1 expression is associated with slowed HD progression and delayed AAO
ID CHR Pos (Mb) TWAS.Z (GeM) TWAS.P (GeM) TWAS.Z (track +registry) TWAS.P (track +registry)
OCA2 15 28.0 0.97 3.30E-01 1.19 2.34E-01
HERC2 15 28.4 0.85 3.95E-01 2.70 6.90E-03
HERC2P9 15 28.9 −1.21 2.28E-01 1.13 2.59E-01
NDNL2 15 29.6 0.07 9.41E-01 1.09 2.76E-01
FAN1 15 31.2 6.99 2.80E-12 −3.78 1.58E-04
CHRNA7 15 32.3 0.10 9.20E-01 −0.01 9.93E-01
ARHGAP11A 15 32.9 −1.49 1.35E-01 0.10 9.21E-01
GREM1 15 33.0 −0.74 4.62E-01 −0.25 8.01E-01
AVEN 15 34.2 −0.48 6.28E-01 0.17 8.67E-01
CHRM5 15 34.3 0.84 4.03E-01 −1.35 1.78E-01
SLC12A6 15 34.5 0.77 4.43E-01 1.57 1.16E-01
NOP10 15 34.6 −0.29 7.74E-01 −1.35 1.78E-01
GOLGA8A 15 34.7 1.66 9.75E-02 −0.56 5.75E-01
GOLGA8B 15 34.8 0.46 6.49E-01 0.64 5.24E-01
AQR 15 35.1 1.01 3.13E-01 −1.76 7.92E-02
ZNF770 15 35.3 0.93 3.54E-01 −0.26 7.92E-01
TWAS results from a 5Mb either side of FAN1 using predictors derived from CommonMind Consortium prefrontal cortex expression data applied to summary statistics
from the GeM study of AAO and the TRACK+REGISTRY study of progression. Positive Z-scores indicate that increased expression associates with later AAO (GeM) or
faster progression. Genes with nominally significant TWAS association are highlighted in red.
role in HD pathogenesis, increasing with age in the tissues most
affected by HD, particularly the striatum, and correlating with
disease onset (3). Despite the correlation of HTT CAG repeat
length with disease course, onset can still differ by several
decades in patients with the same CAG repeat length (4,5). CAG
repeat length accounts for ∼56% of variation in onset (4), but up
to half of the remaining variability is heritable and therefore due
to genetic differences elsewhere in the genome (6).
Recent genome-wide association studies (GWASs) have iden-
tified genetic variation that influences HD age at onset (AAO) at
a chromosome 15 locus that includes the FANCD2 and FANCI
associated nuclease 1 (FAN1) gene with at least two independent
signals, one advancing and the other delaying onset (7). These
data imply polymorphisms in FAN1, a DNA repair enzyme, could
be driving the GWAS signals (7), reinforced by a pathway analysis
that showed DNA repair genes were associated with disease
onset. This suggests that FAN1 may be part of a DNA damage
response (DDR) network that modulates HD pathogenesis (7).
Recent evidence demonstrates Fan1 protects against expansion
of the CGG repeat tract in the Fmr gene in a mouse model of
Fragile X (8). A similar stabilization of the HTT CAG repeat tract
would reduce somatic expansion and could underlie the effect
of FAN1 on HD course.
Functional redundancy is common in the DDR, with com-
ponents participating in multiple independent pathways (9,10).
Interaction between mismatch repair (MMR) and interstrand
cross link (ICL) DNA repair pathways has been reported (10),
with FAN1 capable of compensating for loss of EXO1 MMR activ-
ity under some circumstances (11). Therefore, FAN1 and MMR
components may modulate HD AAO through a shared mech-
anism. A stable physical interaction between FAN1 and MutLα
components MLH1 and PMS2 further supports this hypothesis
(12). FAN1 is a DNA endo/exonuclease involved in DNA repair
that is highly expressed in the brain (12,13). It was originally
identified as a component in the Fanconi anemia (FA) ICL repair
pathway (12,13–16), though its loss does not cause FA but kary-
omegalic interstitial nephritis, a rare recessive kidney disease
caused by loss of FAN1 activity (17–19). FAN1 also regulates
genomic stability and the recovery of stalled replication forks
independent of the FA pathway (20,21). These functions require
FAN1 nuclease activity. FAN1 co-migrates in a complex with
MLH1 and PMS2 that form MutLα, suggesting this complex plays
an important but as yet unidentified role in FAN1 function. This
is pertinent because evidence frommousemodels suggestsMMR
components are required for SI (22,23), and pathway analysis
highlights DNA MMR as a strong driver of HD pathogenesis (7).
TwoMMR components,MSH3 andMLH1, were recently identified
as modulators of HD progression and AAO, respectively (24,25).
As both FAN1 and MMR regulate DNA repeat stability (8,26,27),
interactions between these components suggest they may con-
tribute to a common pathway.
In this study, we find that increased FAN1 expression is sig-
nificantly associated with delayed AAO and slower disease pro-
gression in HD patients. We show FAN1 expression profoundly
suppresses CAG repeat expansion in the U20S cell line express-
ing mutant HTT exon 1, and knockdown (KD) of FAN1 expression
accelerates CAG repeat expansion inHDpatient-derived induced
pluripotent stem cells (iPSCs) and differentiated medium spiny
neurons (MSNs). Further, we show this stabilization is FAN1
concentration-dependent and does not depend on its nuclease
activity. Although FAN1 binds to CAG repeat DNA, we do not
find it is targeted specifically to the expanded repeat sequences.
We propose that FAN1 modulates HD pathogenesis and sta-
bilizes the HTT CAG repeat region by acting in concert with
other DDR proteins. Understanding the mechanism by which
DNA repair components influence disease course may provide
tractable therapeutic targets for HD.
Results
FAN1 has a protective role in HD
A transcriptome-wide association study (TWAS) was performed
to identify genes with expression significantly associated with
altered HD AAO and progression (Table 1). The method of Gusev
et al. (28) was used to impute gene expression values from 452
dorsolateral prefrontal cortex samples from the Common Mind
Consortium (29) into the GeM Consortium (GeM) GWAS of AAO
(7) and the TrackHD and Registry (track + registry) GWAS of
HD progression (24,30). The Z-score represents the standardized
effect size,with positive values indicating that increased expres-
sion is associated with later onset (GeM) or faster progression
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Figure 1. FAN1 expression stabilizes the HTT CAG repeat in culture. (A) Fragment analysis shows the change in modal CAG repeat size over time in U20S FAN1−/− cells
stably transduced with HTT exon 1 (118 CAG). Representative capillary electrophoresis traces are shown withmodal CAG repeat length shown in red text. (B) Increase in
modal CAG repeat size in FAN1−/− and FAN1+/+ cells stably transduced with HTT exon 1 (118 CAG). Note that FAN1 expression (+/+) significantly slows CAG expansion
rate (P = 0.000269, n = 6 for each condition). (C) Cell lysates were prepared for SDS-PAGE from U20S FAN1+/+ , FAN1−/− and cells reconstituted with FAN1GFP-WT, with
or without induction by Tet (0.1 ug/ml). Immunoblots developed with FAN1 or actin antibodies are shown. In the absence of Tet, low levels of GFP–FAN1 are expressed,
close to endogenous expression levels seen in FAN1+/+ cells. Tet induces high FAN1 expression. Note the reduced mobility of the GFP–FAN1 forms. (D) Modal CAG
repeat size in FAN1−/− or FAN1GFP-WT cells (±Tet induction) stably transduced with HTT exon 1 (118 CAG). Data from three replicates for each FAN1GFP-WT condition
and six for FAN1−/− are shown. Tet was included in three of the FAN1−/− experiments shown in this panel but was found to make no significant difference to the
CAG repeat expansion rate so the data were pooled. Note, expression of GFP–FAN1 (WT-Tet) significantly reduces CAG repeat expansion rate (P = 0.000257). Increasing
GFP–FAN1 expression by Tet induction (WT + Tet) further slows CAG repeat expansion.
ber of genes in the TWAS (5261 genes for the Common Mind
Consortium (CMC) cortex) would give a significance criterion of
P < 9.5 × 10−6. Thus, increased FAN1 expression is significantly
associated with delayed AAO of HD. In addition, FAN1 trends
toward significance in the track cohort indicating decreased
FAN1 expression is associated with earlier AAO and faster pro-
gression. That is, FAN1 expression is protective in the context of
an expanded HTT CAG repeat in both cohorts. No other nearby
genes reach nominal significance in both cohorts. Thus, our
TWAS data clearly indicate that FAN1 expression has a role in
modifying HD onset and progression.
FAN1 expression stabilizes the CAG repeat in U20S HTT
exon 1 cells
To investigate how FAN1 expression might modify HD onset and
progression, we introduced wild-type (WT) or variant FAN1 iso-
forms in a tetracycline (Tet)-inducible green fluorescent protein
(GFP) expression cassette into FAN1 knockout U20S osteosar-
coma cells (31) (FAN1−/−; Supplementary Material, Fig. S1). HTT
exon 1 constructs with a range of CAG repeat lengths between
30 and 118 units were stably introduced into these cells by
lentiviral transduction, allowing study of interactions between
FAN1 and HTT CAG repeat DNA. A U20S line expressing endoge-
nous FAN1 provides an additional control (FAN1+/+). GFP–FAN1
constructs were functional in ICL repair and bound known FAN1
interactors FANCD2, MLH1 and PMS2 (Supplementary Material,
Fig. S1).
Firstly, we assessed CAG repeat size within the HTT exon 1
construct of our longest CAG repeat (118 CAG) over extended
periods in culture using fragment analysis. This polymerase
chain reaction (PCR)-based analysis allows accurate sizing of
the CAG repeat. It typically results in a ‘hedgehog’ capillary
electrophoresis trace with a series of peaks separated by one
CAG unit in a roughly Gaussian distribution caused by natu-
ral variation within the sample and PCR stutter (Fig. 1A). The
tallest peak represents the most common or modal value, usu-
ally taken as the CAG repeat size for a given sample. U20S
FAN1−/− HTT exon 1 (118 CAG) showed a smooth, apparently
linear increase in the modal CAG length (Fig 1B). An average
increase in 1 CAG unit increase per 10.1 ± 0.8 days was observed.
The expression of endogenous FAN1 significantly slowed repeat
expansion (FAN1+/+: 1 CAG unit increase per 17.7 ± 1.4 days;
P= 0.000269 compared to FAN1−/− cells; Fig. 1B). Cells expressing
GFP–FAN1 at near endogenous levels (Fig. 1C) were similarly
stabilized (FAN1WT − Tet: 1 CAG unit increase per 14.8 ± 1.1 days;
P = 0.000257 compared to FAN1−/− cells; Fig. 1D). Tet-induced
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Figure 2. HTT CAG repeat stability in culture is length dependent. (A–D) Modal CAG repeat size in FAN1−/− cells stably transduced with the indicated HTT exon 1
constructs. Repeats with 30 CAG and 70 CAG are stable over the culture period of 40 days. The 118 CAG repeats are unstable as expected. The 97 CAG repeats expand
but at a significantly slower rate than the longer 118 CAG repeat (P = 1.38 × 10−5). Data from three replicates per condition are shown.
repeat expansion rate (FAN1WT + Tet: 1 CAG unit increase per
21.3 ± 1.8 days; P = 0.0806 compared with FAN1WT − Tet cells;
Fig. 1D). These data show increasing FAN1 expression correlates
with a slowed CAG expansion rate.
To study the CAG length dependency of the repeat sequence,
a series of HTT exon 1 constructs containing 30, 70 or 97 CAGs
was introduced into FAN1−/− cells. The 30 CAG repeat, which
is a non-pathogenic length, and 70 CAG repeat tracts were sta-
ble in culture over 8 weeks (Fig. 2). This was consistent with
observations of long-term culture of an iPSC line derived from
an HD patient with 73 CAG (Supplementary Material, Fig. S2A).
U20S FAN1−/− HTT exon 1 (97 CAG) cells showed repeat expan-
sion, although the average rate of increase was slower than
that observed in the 118 CAG line (1 CAG unit increase per
18.3 ± 2.2 days; P = 1.38 × 10−5 compared to 118 CAG; Fig. 2).
These data suggest that CAG repeat expansion in cultured cells
is detectable over this short period if long CAG repeat lengths
are used and also demonstrate that the rate of CAG expansion is
length-dependent.
FAN1 nuclease inactivation and the p.R507H
polymorphism do not affect HTT CAG repeat stability in
U20S cells
To investigate which aspects of FAN1 function regulate CAG
repeat stability in the U20S cells, FAN1 variants were introduced
into the WT GFP–FAN1 construct by site-directed mutagenesis;
the p.D960A mutation inactivates the nuclease domain (14,15),
and the p.R507H variant within the DNA-binding domain was
themost significant coding small nuclear polymorphism in FAN1
from theGeMHDGWAS (7).Western blot analysis confirmed pro-
tein expression in FAN1−/− cells reconstituted with these FAN1
forms but showed that FAN1 levels varied. Quantification of
immunoblots showed that the p.R507H variants were expressed
at 1.2–1.5 times the levels of the WT protein (Fig. 3A). U20S cells
expressing either WT or p.R507H FAN1 were fully functional in
ICL repair (Fig. 3 and SupplementaryMaterial, Fig. S1). Consistent
with this, lymphoblastoid (LB) cells derived from patients with
WT or p.R507H FAN1 also showed equivalent ICL repair activity
(Supplementary Material, Fig. S1). As expected, FAN1−/− and
the nuclease-inactivated p.D960A mutation, either on a WT or
p.R507H FAN1 background, increased mitomycin C (MMC) sensi-
tivity, indicative of compromised ICL repair function (Fig. 3B).
These cells were transduced with the 118 CAG HTT exon
1 construct, and the stability of the trinucleotide repeat was
assessed (Fig. 3C–F). There was no significant difference in CAG
expansion rate in cells expressing the WT or nuclease-dead
D960A mutant (P = 0.331 FAN1WT compared with FAN1WT D960A).
CAG repeat expansionwas significantly slower in both lines than
FAN1−/− cells transduced in parallel (FAN1WT and FAN1WT D960A
P= 1.96× 10−8). Similarly, expression of the D960Amutation on a
p.R507H background did not affect expansion rate relative to the
catalytically active p.R507H isoform (P = 0.882, FAN1p.R507H com-
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Figure 3. FAN1 nuclease activity and p.R507H polymorphism do not influence HTT CAG repeat stability. (A) Immunoblot showing FAN1 levels in U20S cells reconstituted
with catalytically active or nuclease-dead WT or p.R507H variant FAN1 forms. The FAN1−/− line is shown for comparison. Note that the p.R507H variant and p.R507H
D960A forms are expressed at a higher level. (B) U20S cell lines were treated with MMC at various concentrations for 16 h. The cells were washed into fresh media and
viability was assessed after 10 days in culture. FAN1−/− and nuclease-dead mutant lines are equally vulnerable to MMC toxicity. Catalytically active FAN1 forms infer
protection. Data from three replicates per condition are shown. (C–F)Modal CAG repeat size in FAN1−/− cells reconstituted with FAN1 isoforms, as indicated, and stably
transduced with HTT exon 1 (118 CAG); linear trend lines have been fitted to the data. CAG expansion rate did not differ betweenWT, p.R507H, p.D960A (nuclease-dead)
or the combined p.R507H + p.D960A cell lines. Data from three (p.R507H forms) or four (WT forms) replicates per condition are shown.
expansion relative to FAN1−/− cells (FAN1p.R507H P = 2.08 × 10−11
and FAN1p.R507H D960A P = 1.58 × 10−9). There was a trend toward
slower CAG repeat expansion in cells expressing the p.R507H
FAN1 isoform (FAN1p.R507H P = 0.0692 relative to FAN1WT). These
results suggest that the nuclease domain is not required for
FAN1 to stabilize the HTT CAG repeat and that the p.R507H vari-
ant does not significantly increase CAG repeat expansion rate.
FAN1 expression regulates the stability of the
endogenous CAG repeat in HTT
To assess the stability of the CAG repeat in the endogenous
HTT gene, we used iPSCs derived from an HD patient with 109
CAG repeats (32). At baseline, the CAG repeat was measured at
121 units, indicating expansion from the original length, and
during characterization of the cells over 58 passages the repeat
expanded to 131 units. Expansion in long-term culture fits to an
exponential model (r2 = 0.99, P = 7.65 × 10−26) (Supplementary
Material, Fig. S2B). Current cells have been in culture for 300 days,
have a CAG length of 147 repeats, expand at a rate of 1 CAG repeat
every 12.4 days and would be predicted to reach 200 repeats in
19 months.
To verify the effects of FAN1 on the CAG repeat region in the
endogenousHTT gene,we introduced shRNA targeting FAN1 into
this cell line using retroviral transduction. FAN1 expression was
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Figure 4. FAN1 expression regulates the stability of the endogenous CAG repeat in HTT gene. (A) qPCR showing gene expression in the 109 CAG iPSC line and
differentiated MSNs derived from this line following stable introduction of an shRNA targeting FAN1. Control cells and empty vector-treated cells are also shown.
Expression of FAN1 was significantly reduced by the introduction of shRNA (53.1% KD in iPSCs, P = 0.017), whereas transcript levels of HTT, MSH3 and MLH1 were
unchanged. FAN1 KD was maintained throughout differentiation. MSN cells were harvested at day 36 on the scale shown in panel (E) for this analysis. Data from three
independently transduced or mock-treated (control) lines are shown. (B) Western blot shows FAN1 KD in the 109 CAG iPSC line following stable introduction of an
shRNA targeting FAN1. (C) Change in modal CAG repeat size over time is shown for control 109 CAG iPSC cells (green) or cells treated with shRNA targeting FAN1 (blue)
or control empty vector (gray). Note the increased rate of expansion in the cells lacking FAN1. Data points represent mean ± SEM from three iPSC lines transduced
independently for each treatment group. Linear trend lines have been fitted to the data. Statistical analysis indicated significant difference in expansion rate between
FAN1 KD and control (P = 1.579 × 10−8). (D and E) SI of the CAG repeat region from the iPSC lines with 109 CAG continues in post-mitotic neurons. (D) Confocal image
of 109 CAG cell line following MSN differentiation. The images were taken at day 36 on the scale shown in panel (E). Note the expression of DARPP32 (green), MSN
marker CTIP2 (red) and neuronal marker βIII tubulin. DAPI (blue) is included in the merged image (scale bar 20 μm). (E) Change in CAG repeat length over time. FAN1
KD accelerates CAG expansion in differentiating cells. Data points represent mean ± SEM from three iPSC lines transduced independently for each treatment group.
Linear trend lines have been fitted to the data. Statistical analysis indicated significant difference in expansion rate between FAN1 KD and control (P = 6.15 × 10−7).
KD was maintained over the period of the experiment (Fig. 4A
and B). Expression ofHTT andMMR componentsMLH1 andMSH3
were not affected (Fig. 4A).
The CAG repeat increased in size in the control and empty
vector-treated cells at a similar rate (1 CAG unit every 17.7 ± 1.1
and 16.1 ± 1.2 days; P = 0.573). However, FAN1 KD significantly
increased expansion rate to 1 repeat every 9.1 ± 0.5 days (Fig. 4C;
P = 7.81 × 10−7 as compared to untreated and empty vector-
treated cells). These results support data from U20S cells, sug-
gesting that FAN1 protects against expansion of the endogenous
HTT CAG repeat, at least in mitotic cells.
To assess if this mechanism also operates in non-dividing
cells, we used an established differentiation protocol to generate
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Significantly increased expression of a panel of MSN markers,
including BCL11B (CTIP2), DRD1, DRD2, GAD2, TAC1, OPRM1,
PENK and CALB1, as well as the neuronal markers DARPP32
and βIII relative to iPSCs, demonstrates that a high proportion
of mature striatal neurons were generated by day 36 of this
protocol (Fig. 4D and Supplementary Material, Fig. S3). Serial
cultures were grown and harvested during differentiation and
as the MSNs age up to day 70. Western blot and quantitative
PCR (qPCR) showed that FAN1 KD was maintained throughout
differentiation (Fig. 4A and B). Fragment analysis showed that
CAG expansion rate was equivalent in the untreated differen-
tiated MSNs and untreated iPSCs (1 repeat every 17.7 ± 1.1
and 16.7 ± 2.3 days). CAG expansion rate was not significantly
different in untreated and empty vector-treated MSNs (1 repeat
every 23.7 ± 2.8 days for the latter; P = 0.661). Critically, FAN1
KD significantly increased CAG expansion rate to 1 CAG repeat
every 9.1 ± 0.6 days (P = 0.00167 compared to control and empty
vector-treated cells).These data suggest that FAN1 restrains CAG
repeat expansion in cultures that contain a high proportion of
differentiated post-mitotic striatal neurons (Fig. 4).
FAN1 associates with the HTT CAG repeat
FAN1 interactions with CAG repeat DNA in HTT exon 1 were
assessed using chromatin immunoprecipitation (ChIP) assays.
Initially FAN1−/−, GFP–WT- or GFP–p.R507H-expressing U20S
cells were transiently transfected with the HTT exon 1 fragment
containing 118 CAG repeats to introduce high copy numbers
of the plasmid DNA. FAN1 expression was maximized by Tet
induction, optimizing conditions for detecting an interaction
with the HTT exon 1 DNA. This system permits pull down of
GFP–FAN1 forms and associated DNA using highly specific and
efficient GFP-Trap beads (ChromoTech, Germany). ChIP fractions
were probed by PCR with primers spanning the CAG repeat.
Low but reproducible levels of CAG repeat DNA were detected
in the ChIP fractions from cells expressing both GFP–FAN1 WT
and p.R507H variant forms (Supplementary Material, Fig. S4A).
ChIP fractions from the control FAN1−/− cells did not contain
detectable DNA, demonstrating the specificity of the ChIP pull
down. These results suggest a novel interaction between FAN1
and CAG repeat DNA.
We then made use of our panel of U20S cells expressing GFP-
WT or GFP–p.R507H FAN1 and stably transducedwithHTT exon 1
of 70, 97 and 118 CAG repeat lengths. TheHTT CAG fragments are
integrated and transcriptionally active (SupplementaryMaterial,
Fig. S4B and C). Again GFP-Trap beads were used to pull down
GFP–FAN1 forms, with corresponding FAN1−/− cells acting as
controls. Primers spanning the HTT CAG repeat amplified low
levels of DNA from ChIP fractions isolated from U20S HTT exon
1 cells with 70 CAG repeats. In addition, these ChIP fractions
contained amplified DNA derived from the endogenous, non-
pathogenic HTT gene (20 CAG repeat units), as visualized as a
doublet on an agarose gel (Fig. 5A). As expected, ChIP fractions
from control FAN1−/− cells did not contain detectable levels of
DNA. Similar levels of PCR product were generated from ChIP
fractions derived from WT and p.R507H variant FAN1 forms. No
clear differences in the levels of the shorter (WT allele) or longer
(introduced exon 1 DNA) CAG repeat DNA could be discerned.
To demonstrate that FAN1 interacts with expanded CAG
repeat DNA of the endogenous HTT gene we utilized LB cells
from two HD patients with similar FAN1 expression levels,
one homozygous for WT FAN1 and the other heterozygous
for the p.R507H variant (Supplementary Material, Fig. S1). To
isolate ChIP fractions, a highly specific FAN1 antibody was used
(Supplementary Material, Fig. S1). The mutant HTT allele in
these cells contains 42 and 43 CAG repeats. Input and ChIP
fractions were isolated and probed with the primers spanning
the CAG repeat. PCR products are visualized as a doublet on the
agarose gel,most clearly seen in the input fractions (Fig. 5B).ChIP
fractions from both WT and p.R507H FAN1 cell lines contained
low but reproducible levels of PCR product derived from both
long and short HTT alleles, indicating that FAN1 interacts
with both the normal and mutant HTT CAG repeats. Both
contained similar levels of PCR product (Fig. 5B). Control ChIP
reactions in which the FAN1 antibody was omitted contained
low background levels of CAG repeat DNA.
To determine the specificity of FAN1’s interaction with HTT
CAG repeat DNA, we quantified the DNA fragments isolated in
the FAN1 ChIP fractions by qPCR. Together with the primers
spanning the CAG repeat, pairs targeting two regions of HTT, one
proximal to the CAG repeat region and one distal at the 3′ end of
the gene, along with others targeting different genes with CAG
repeat regions and other control genes, were used to probe the
ChiP DNA (Fig. 5C). We found no significant enrichment for the
HTT CAG repeat or indeed any of the CAG repeat DNA from other
genes (Fig. 5C). Thus, FAN1 is not detectably targeted to the CAG
repeat region of HTT.
We performed similar experiments using the 109 CAG
iPSCs, which are homozygous for WT FAN1 and containing
an unstable HTT CAG repeat (Supplementary Material, Fig. S4).
ChIP fractions isolated using the FAN1 antibody contained
DNA amplified from both long and short HTT alleles with no
obvious differences in amount detectable. qPCR showed the
ChIP fractions contained similar levels of DNA amplified with
primers spanning the CAG repeat or control regions of HTT
(Supplementary Material, Fig. S4).
Discussion/Conclusion
Recent GWAS have identified a locus on chromosome 15, likely
underlain by FAN1, as a modifier of HD onset (7). Through
a TWAS, we demonstrate that increased FAN1 expression is
significantly associated with delayed HD onset and slower
disease progression. This suggests that FAN1 is protective in
the context of an expanded HTT CAG repeat. We used a series
of cell models to show that WT FAN1 restrains CAG repeat
expansion in both dividing and post-mitotic HDMSNs. Expanded
HTT CAG repeats are somatically unstably in vivo, and CAG
repeat expansion correlates with tissue-specific neuropathology
and disease severity (3). Our data suggest that increased FAN1
expression delays HD onset and slows progression by restricting
CAG somatic expansion.
FAN1 is the only gene significant in GeM TWAS and trends
toward significance in the TRACK cohort (Table 1), suggesting its
expression level in cortex influences HD phenotype. While it is
possible that other genes at the chromosome 15 locus, such as
MTMR10, are driving the GWAS signal, the data presented here
strongly support FAN1 as the HD modifier.
Recent evidence that FAN1 restricts GCC trinucleotide repeat
DNA expansion in a mouse model of Fragile X is consistent with
our data (8). This supports our hypothesis that FAN1 modulates
HD course by stabilizing the HTT CAG repeat. FAN1 is likely
to play a key role in a network of DDR proteins, as suggested
by GWAS pathway analyses that find significant association of
DNA repair gene sets independent of FAN1 (7,24,25). These path-
ways include MMR components MSH3 and MLH1; inactivation
of which in HD mouse models abrogates somatic expansion
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Figure 5. FAN1 associates with the HTT CAG repeat. (A) U20S HTT exon 1 70 CAG FAN1 knockout (−/−) cells or cells reconstituted with WT or p.R507H proteins were
prepared for ChIP. GFP-Trap beads were used to isolate FAN1 forms and associated DNA. Agarose gel showing input (5%) and ChIP fractions amplified with primers
spanning the HTT CAG repeat. The two bands visualized using CAG primers in the input and ChIP fractions are DNA amplified from the introduced HTT exon 1 plasmid
(70 CAG units) and DNA from the endogenous HTT gene (20 CAG units). ChIP fractions isolated FAN1−/− cells did not contain detectable amounts of DNA, indicating
the specificity of the ChIP procedure. (B) Extracts from HD LB cells homozygous for WT FAN1 or heterozygous for the p.R507H variant were prepared for ChIP analysis,
and a FAN1 antibody was used to isolate FAN1 and associated DNA. Mock pull downs with no antibody were used as controls. Primers spanning the CAG repeat of the
HTT gene were used to amplify isolated DNA. PCR products were visualized on an agarose gel. Input (5%) and ChIP fractions are shown. The two bands seen in the
input and ChIP fractions are amplified DNA from normal and mutant expanded HTT alleles. Controls without antibody contained little DNA showing the specificity of
the ChIP experiment. (C) ChIP fractions shown in (B) were amplified with primer pairs targeting different regions of HTT (CAG repeat and non-CAG regions—HTT con 1
proximal to the repeat and 2 targeting the 5′ end of HTT) and other CAG repeat-containing genes regions. The data indicate that FAN1 is not specifically targeting the
HTT CAG repeat region. The mean from three independent experiments is shown (error bars = standard deviation).
suggest that FAN1 also contributes to this mechanism, protec-
tively inhibiting CAG expansion.
Repeat instability likely involves the formation of unusual
DNA secondary structures such as slipped strands,hairpin loops,
G-quadruplexes and R-loops during DNA transcription, replica-
tion and repair (34). The high complementarity of the repeating
sequence can lead to slippagemutation ormishybridization (35).
These features are recognized by DNA repair proteins, notably
members of the MMR pathway and its co-factors, which may
trigger attempts at repair that lead to the incorporation of addi-
tional CAG units. Longer CAG repeats are more unstable and
prone to increased rates of expansion (35), a feature recapitu-
lated in our U20S cells expressingHTT exon 1with a series of CAG
repeat lengths (Fig. 2). Over the short 40 day time course of our
U20S assay, we observed a steadily increasing CAG repeat with
a linear regression fitting our data closely. However, extended
culture of 109 CAG iPSCs show CAG repeat expansion fits best
to an exponential model, as would be expected (Supplementary
Material, Fig. S2B). Patient cells with CAG repeat lengths typical
of HD remain stable in culture. Even iPSCs and MSNs derived
from a patient with a repeat of 73 CAG, a mutation causing
juvenile onset HD, remained stable in culture for over 150 days
(Supplementary Material, Fig. S2A). This may reflect the rarity
of expansion events, particularly in shorter repeats, and it may
be that instability can only be detected in these lines following
significantly extended culture. In support of this, SI has been
observed in mouse lines with similar CAG repeat sizes over a
9–24 month time frame (36,37). HD typically manifests in midlife
and it has been suggested that this reflects slow somatic expan-
sion of the CAG repeat over decades until a toxic threshold is
reached, after which expression of a highly toxic polyglutamine
tract, particularly in vulnerable tissues, causes disease (3,37,38).
The mechanism by which FAN1 exerts its protective effect is
unknown but different models can be postulated (Fig. 6). FAN1,
which is structure rather than sequence-specific (39), may bind
abnormal DNA structures formed by the CAG repeat, physically
blocking access of other DNA repair proteins and preventing
error-prone repair. Alternatively, FAN1 may promote accurate
repair of the CAG repeat, either directly or by acting as a scaffold
for assembly of a protein complex. Our ChIP results suggest
FAN1 binds at or very near the CAG repeat, possibly recognizing
unusual conformations formed by this type of sequence (40).
However, we were unable to demonstrate any enrichment for
mutant CAG repeat DNA in the ChIP fraction, indicating that
FAN1 does not preferentially interact with the expanded CAG
sequence. In addition, the p.D960A mutation which inactivates
FAN1’s nuclease activity did not impair its ability to stabilize
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Figure 6. Mechanism of CAG repeat stabilization schematic showing a possible mechanism of FAN1 action. MutSβ (MSH2/MSH3) binds to abnormal structures formed
by CAG repeat DNA, represented by a hairpin loop in the top strand. In the absence of FAN1 (purple box, FAN1−/−), MutLα (MLH1/PMS2) is recruited to the lesion by
MutSβ. This leads to MMR activation, error-prone repair and CAG expansion. FAN1 expression (green box) may stability the CAG repeat by sequestering MutLα. This
prevents its interaction with MutSβ thereby stopping MMR activation and CAG expansion. Alternatively, the association of FAN1with the CAG repeat facilitates accurate
repair, possibly by recruiting DDR components or FAN1 blocks access to the CAG repeat, preventing access to MMR components and CAG expansion.
the high expression levels used in our U20S cell model will not
generate any nuclease activity (as demonstrated in ICL repair
assays; Fig. 3). This observation is unusual in FAN1 biology, with
all functions identified to date depending on its nuclease activity
(12,18–21,41). Our data suggest a novel FAN1 activity is regulating
CAG stability.
The FAN1 interactome includes several proteins already
known to affect CAG repeat stability, includingMutL components
(MLH1, MLH3 and PMS2) and proliferating cell nuclear antigen
(PCNA) (12,41). FAN1 is recruited to stalled replication forks by
ubiquitinated PCNA (41), but no function has yet been described
for the interaction with MLH1, despite evidence indicating this
complex is stable, and comprises a substantial proportion of
the cellular FAN1 and MLH1 under steady-state conditions (12).
MutLα components MLH1 and PMS2 are readily detectable in
GFP-Trap pull down fractions from U20S cells expressing GFP–
FAN1 (Supplementary Material, Fig. S1), whereas MutSβ does
not bind to FAN1 (12). Therefore, FAN1 may sequester MLH1,
preventing its interaction with MSH3 and the assembly of the
MMR complex that promotes HTT CAG repeat expansion (Fig. 6).
The GeM HD GWAS suggest that the p.R507H FAN1 variant
is associated with earlier onset (7), so one would anticipate
accelerated expansion in cells expressing it. U20S HTT exon 1
(118 CAG) cells expressing p.R507H showed reduced CAG repeat
expansion rates compared to those expressing WT forms which
trended toward significance. However, given the large effect size
of FAN1 protein level (Figs 1 and 4), these changes are likely
due to differences in FAN1 expression rather than alteration
of intrinsic protein function. It may be that our assay systems
are not sensitive enough to detect small changes in activity
that the p.R507H variant may engender. This is relevant because
GWAS variants are often hypomorphic and the relatively high
FAN1 levels expressed in the U20S cells could obscure subtle
differences in activity between WT and p.R507H variant FAN1.
This contrasts with the p.D960A mutation, which is known to
have profound effects on FAN1 nuclease activity, compromising
ICL repair activity in our U20S cell system to the level seen in
FAN1−/− cells (Fig. 3).
We have shown that the DNA repair protein FAN1 stabilizes
the expandedHTT CAG repeat in cellmodels and patient-derived
cells. Critically, this includes post-mitotic striatal MSNs gener-
ated from human HD iPSCs. These neurons model the region
most vulnerable early in HD pathogenesis and that show the
highest levels of SI (3,36,37). Therefore, they represent the most
physiologically relevant in vitro model available to study SI. In
the context of HD, FAN1 activity is predicted to reduce somatic
expansion and thereby delay onset and slow disease progres-
sion. Our TWAS data are consistent with this hypothesis, sug-
gesting that increased FAN1 expression delays onset and slows
progression. DNA repair variants that modify disease course in
HD also influence onset in other polyglutamine diseases (42), so
modulation of FAN1 may have therapeutic potential in a range
of neurodegenerative diseases caused by repeat expansion.
Materials and Methods
Transcriptome-wide association study
The method of Gusev et al. (28) was used to test for association
between phenotype data from the GWAS summary statistics
from the HD AAO in the GeM cohort (n = 4082) and HD pro-
gression in the combined track + registry cohort (n = 2078) and
gene expression in control dorsolateral prefrontal cortex from
the Common Mind Consortium (n = 452).
Cell culture and manipulation
U20S SEC-C, HEK293T and Phoenix Ampho cells were grown in
Dulbecco’s minimal essential medium (DMEM) with GlutaMAX
supplementedwith fetal bovine serum (FBS) (10%) and pen/strep.
FAN1 knockout and reconstitution were carried out as described
previously (31). FAN1 mutants were generated by site-directed
mutagenesis using the QuickChange XL kit according to the
manufacturer’s instructions (Agilent, CA, USA). The presence
of the DNA base changes was confirmed by sequencing of
the genomic DNA isolated from reconstituted cells. The HTT
exon 1 series with increasing CAG length was encoded in
p’HRsincpptUCOE+htt IRES eGFP. Human HTT exon 1 lentiviral
plasmids and related control vectors were previously described
(43). This was transfected directly using GeneJuice for transient
experiments or packaged in lentiviral particles for stable
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vectors and p’HRsincpptUCOE+htt IRES eGFP using Lipofec-
tamine LTX. After 16 h, 8 ml fresh media was added. Cell
media containing mature lentivirus was harvested 48 h post-
transfection. This was filtered and frozen at −80◦C or used
directly.
For CAG expansion assays HEK293T-conditioned media con-
taining p′HRsincpptUCOE+htt lentivirus was mixed one to one
with fresh media supplemented with polybrene (8 μg/ml) and
added to U20S cells for 24 h prior to a completemedia change. At
this point, Tet was added if appropriate and this was considered
to be the start of each time course. Cells were grown to 80–
90% confluence and sub-cultured 1:20 using (TrypZean, Sigma
Aldrich, UK) to lift the cells. Excess cells were washed in phos-
phate buffered saline (PBS) and then frozen as a semi-dry pellet
prior for genomic DNA extraction. The data shown are from
three to six independent time course experiments. LB cells were
grown in Roswell Park Memorial Institute (RPMI) supplemented
with 15% FBS (non-heat inactivated), glutamine and pen/strep.
For ICL repair assays, MMC was added to cells at increasing
concentrations for 16 h. Cells were washed into fresh media and
plated at 200 cells per well in a 96 well plate. Cells were cultured
for 10–14 days and then the proportion of live cells was assayed.
Cell survival was expressed as a percentage of control untreated
cells. For acute MMC (200 ng/ml) or cisplatin (1 μg/ml) treatment
drug was added for 2 h and then the cells were cultured in fresh
media for 24–72 h prior to use. H2Ax foci clearance was assayed
as described previously (12).
The shRNA hairpin targeting FAN1 (target sequence: GTAAG-
GCTCTTTCAACGTA) was subcloned into pSUPER.retro.Puro and
transfected into Phoenix Ampho packaging cells using Lipo-
fectamine LTX. After 16 h, 8 ml fresh media was added. Cell
media containing mature retrovirus was harvested 48 h post-
transfection. This was filtered and frozen at −80◦C or used
directly.
iPSC culture and manipulation
Stem cells were maintained in Essential E8 medium (Ther-
moFisher) on Thermo-Nunc plasticware coated with Geltrex
(Gibco) diluted 1:50 in DMEM/F12 without glutamine. They were
passaged bymanual dissociation using 0.02% EDTA (Gibco).MSN
differentiation was carried out as described (32) using Activin A
to direct ganglionic/striatal fate. Media containing retrovirus
encoding shRNA hairpins targeting FAN1 or empty vector was
mixed one to one with normal iPSC media and supplemented
with polybrene (8 μg/ml). This media was added to iPSC at ∼70%
confluence and the cells were incubated for 16 h. Fresh media
was added to the cells for a further 48 h prior to selection. For
this, the media was supplemented with puromycin (1 μg/ml)
and the cells were monitored ensuring regular media changes
to minimize the number of dead cells in the culture. Colonies of
transduced cells were detected after 2–3 weeks. Untreated cells
were cultured alongside the selected cells and used as controls
in subsequent experiments.
Fragment analysis ChIP and real-time qPCR
Fragment analysis was performed using standard methods with
primer sequences detailed below. Samples were run on an
ABI 3730 Genetic Analyser and analyzed using GeneMapper
software (Thermo). For ChIP analysis cells were collected,
washed in PBS and then cross linked with formaldehyde (1%
final concentration) for 10 min at a room temperature. Excess
formaldehyde was quenched by adding glycine to 125 mm and
incubating for 5 min. Cross linked cells were pelleted, washed
in PBS and frozen at −80◦C or used directly. Cells were lysed
in lysis buffer [15 mm Tris–HCL, pH 7.5, 0.3 m Sucrose, 60 mm
KCl, 15 mm NaCl, 5 mm MgCl2, 0.1 mm EGTA, 0.5 mm DDT and
0.2% IGEPAL-CA supplemented with protease inhibitors] and
nuclei were pelleted at 20 000 g for 20 min. Supernatants were
aspirated and nuclei were resuspended in sonication buffer
(50mmTris, pH 8.0, 10mmEDTAand 1% sodiumdodecyl sulphate
(SDS) supplemented with protease inhibitors). Chromatin was
fragmented by 10 cycles of 30 s sonication in a Bioruptor
apparatus. Ice water was added to the sonication bath to ensure
that temperature was regulated during disruption. Insoluble
material was cleared by centrifugation at 20 000 g for 10 min.
This sonicated fraction was used diluted 10-fold with dilution
buffer (16.7 mm Tris pH 8.0, 1.2 mm EDTA, 167 mm NaCl and 1%
Triton X-100 supplemented with protease inhibitors) and used
as the ChIP input. Immunoprecipitation was done overnight
at 4◦C using GFP-Trap beads to capture GFP–FAN1 forms or an
affinity-purified FAN1 sheep polyclonal antibody and protein G
magnetic beads (20 μl of either bead per reaction). The isolated
ChIP fractions were washed twice in Wash Buffer 1 (20 mm Tris–
Cl, pH 8.1, 50 mm NaCl, 2 mm EDTA, 1% Triton X-100, 0.1% SDS),
once inWash Buffer 2 (10 mm Tris–Cl, pH 8.1, 150 mm NaCl, 1 mm
EDTA, 1% NP40 and 1% Na deoxycholate) and once in Tris–EDTA.
Bound material was eluted at 65◦C for 30 min in 1% SDS and
sodium 0.1 m NaHCO3. Cross links were reversed in ChIP and
input fractions by adding NaCl to 250 mm and proteinase K (PK)
(2 μl of 0.5 mg/ml PK per reaction) and heating at 65◦C for at
least 4 h. DNA was purified using columns and subjected to
PCR using the following primers (genomic positions are given
in brackets): HTT con 1 forward TTTGCCCAGGGAATCTTTGC,
reverse TTGCAAGCGGAGAGAGAAGA (25886-26037); HTT con
2 forward TGCCTTTCGAAGTTGATGCA, reverse TGCCACCAC-
GAATTTCACAA (137990-138191); HTT CAG 1 forward GAGTC-
CCTCAAGTCCTTCCAGCA, reverse CTGAGGAAGCTGAGGAGGC
(179-309); HTT CAG 2 forward GAGTCCCTCAAGTCCTTCCAGCA,
reverse GCCCAAACTCACGGTCGGT (179-426); TBP control
forward AAGAGTGTGCTGGAGATGCT, reverse ATGCCCTTC-
CTTGCCTTTTG (2605-2831); TBP CAG forward CAGCCAGCC-
TAACCTGTTTT, reverse CTGCCTTTGTTGCTCTTCCA (7421-7577);
ATXN3 control forward TATCCGTCTTGCAAGGTGGT, reverse
CCCTGAATTGACGGCAGATG (7359-7534); ATXN3 CAG forward
TTCAGACAGCAGCAAAAGCA, reverse AAAGTGTGAAGGTAGC-
GAACAT (35564-35732); DMPK control forward TGGGCCCAAA-
GACTCCTAAG, reverse TCTGAAGTCCTGTGGCTCTG (12722-
12893); and FXN control forward AAGCGTGCATTTTGGATTCAA,
reverse TTTTCAATTCCCTCACTGTCCTT (24300-24488). Quantifi-
cation was done using Sybr Green reagents and a QuantStudio
real-time PCR machine and software. MSN gene expression was
assayed using Taqman Fast Advanced Master Mix and probes
(ThermoFisher, Scientific, UK). Data were analyzed using the 2–
Ct method, with ACTB, ATP5B, EIF4A2 and SDHA as house-
keeping genes and normalized to the control 109Q iPSC line.
Western blot and immunoprecipitation
Cell extracts were prepared for SDS-polyacrylamide gel elec-
trophoresis (PAGE) as described previously (44). The antibodies
used were a FAN1 sheep polyclonal antibody generated for this
study; MSH3 or MLH1 monoclonal antibodies (BD Biosciences,
UK); HTT exon 1-specific monoclonal antibodies 4C9 (Millipore,
Merck-Millipore, UK) and MSH2 (Cell Signaling Technology, Dan-
vers,MA,USA); and PMS2,GAPDH andGFP rabbit polyclonal anti-
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were quantified with the Odyssey CLx Imaging System,
(Lincoln, NE, USA) using Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) and β-actin as loading controls. For Immuno-
precipitation (IP) analysis, washed cells were resuspended in
IP buffer (20 mm Tris, pH 7.4, 150 mm NACl, 1 mm EDTA, 1%
Triton X-100 supplemented with Benzonase 2 U/ml and protease
inhibitors) and incubated on ice for 20min.The cell extractswere
centrifuged at 10 000 g for 2 min and the supernatant fraction
was used as input. GFP-Trap beads or the FAN1 goat polyclonal
and MSH3 or MSH2 monoclonal antibodies and protein G
magnetic beads were used to capture protein complexes. Beads
were washed 3 times in IP buffer and eluted by heating in SDS
sample buffer.
Statistical analysis
Curve estimation was performed in SPSS (IBM) by producing
regression statistics for 11 different models. Variance from the
model and significance was measured by analysis of variance.
Expansion ratewas calculated from the slope of linear regression
model fitted to change in modal CAG repeat length and was
expressed as number of days per change in modal CAG length
(±95% confidence interval). Expansion rates of treated or empty
vector cells were compared with control cells by analysis of
variance between the slopes of the linear regression lines in
SPSS (IBM).
Testing for differences in rate of CAG expansion
between treatments
The rate of CAG expansion was modeled as a linear regres-
sion of CAG expansion on the number of days since the start
of treatment. Differences in rate of CAG expansion between
treatments were modeled by the inclusion of a days∗treatment
interaction term in the regression, and the significance of this
term determines the significance of CAG expansion rate differ-
ences between treatments. Correlations between multiple CAG
expansion measurements from the same replicate cell line were
modeled by including cell line-specific random effects on CAG
expansion rate in the analysis.Models were fitted using the lmer
function in R.
Initially, global differences in CAG expansion rate were
tested between all treatments simultaneously. If this test was
significant, post-hoc tests were performed to characterize the
differences.
Supplementary Material
Supplementary Material is available at HMG online.
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